Maven Bio

Maven Bio, previously named RightPage, operates from Boston, MA, and focuses on the B2B operations subindustry within biotech and healthcare. The company, which has a team of three, is part of the Y Combinator S23 batch and serves the United States and Canada, offering both remote and partly remote services. Maven Bio’s platform employs generative AI to deliver evidence-backed insights specifically tailored for corporate development teams in the biopharma industry. The platform is designed to facilitate rapid construction of deal landscapes and comparative analyses, aiming to reduce the commercial failure rate of drugs by 50%. Additionally, Maven Bio plans to broaden the scope of its platform by incorporating more comprehensive assessments of therapeutic opportunities.